First Quadrant’s Precision BioSciences DTIL Stock Holding History

First Quadrant’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3	Closed	-$1K	–	582
2020 Q4	$1K	Buy	+3	New	+$735	﹤0.01%	575

Other funds holding DTIL

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Quadrant's DTIL Position: Q1 2021 in Review

First Quadrant sold out of Precision BioSciences (DTIL) in Q1 2021, closing a stake of 3 shares — an estimated $1K sold.

First Quadrant first reported a position in DTIL in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 128 funds tracked by Wall St. Rank hold DTIL as of Q1 2021.

First Quadrant reported no remaining Precision BioSciences position as of Q1 2021 after selling out during the quarter.
First Quadrant sold 3 Precision BioSciences shares in Q1 2021, an estimated $1K.
First Quadrant first reported a position in Precision BioSciences in Q4 2020 and held it in 1 quarter.
First Quadrant's Precision BioSciences position peaked at $1K in Q4 2020.
128 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2021.

Based on First Quadrant's 13F filing for Q1 2021, filed 27 Apr 2021.